Prophylactic HIV Drugs Market

Executive Summary

Prophylactic HIV Drugs Market was valued at US $31.46 billion in 2021 and is projected to grow at 4.87% CAGR over the forecast period to reach US $41.86 billion by 2027. Prophylactic HIV Drugs Market represented US $2.86 billion opportunity over 2019-2021 and estimated to create US $10.40 billion opportunity in 2027 over 2021.

Prophylactic HIV Drugs from Consainsights analyses the Prophylactic HIV Drugs Market in the Life Sciences industry over the forecast period to 2027.

Prophylactic HIV Drugs research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Prophylactic HIV Drugs segmentation includes Drug, Dosage Form and Geography.

Based on the Drug, the Prophylactic HIV Drugs analysis covers Tenofovir, Emtricitabine, Other Drugs.

In Drug segment, Emtricitabine segment has highest cagr growth of 4.32%.

Based on the Dosage Form, the Prophylactic HIV Drugs analysis covers Oral, Topical.

In Dosage Form segment, Topical segment has highest cagr growth of 4.32%.

Based on the region, the Prophylactic HIV Drugs analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include AbbVie, APOTEX INC., Auro Pharma Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cipla Inc., GalaxoSmithKline PLC, Genentech Inc., Gilead Sciences Inc., Johnson & Johnson Health Care Systems Inc., Merck & Co. Inc., Mylan NV, Pfizer Inc., Teva Pharmaceutical Industries Ltd, ViiV Healthcare Group of Companies and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Drug

Introduction

In 2021, Tenofovir segment has the highest revenue of US $19.99 billion and is expected to grow at CAGR of 4.32% by 2027 Emtricitabine segment has highest cagr growth of 4.32%.

Tenofovir

Tenofovir segment was valued at US $18.18 billion in 2019 and is projected to grow at 4.32% CAGR over the forecast period to reach US $26.60 billion by 2027. Tenofovir segment represented US $1.81 billion opportunity over 2019-2021 and estimated to create US $6.61 billion opportunity in 2027 over 2021.

Emtricitabine

Emtricitabine segment was valued at US $5.32 billion in 2019 and is projected to grow at 4.32% CAGR over the forecast period to reach US $7.78 billion by 2027. Emtricitabine segment represented US $0.53 billion opportunity over 2019-2021 and estimated to create US $1.93 billion opportunity in 2027 over 2021.

Other Drugs

Other Drugs segment was valued at US $5.11 billion in 2019 and is projected to grow at 4.32% CAGR over the forecast period to reach US $7.48 billion by 2027. Other Drugs segment represented US $0.51 billion opportunity over 2019-2021 and estimated to create US $1.86 billion opportunity in 2027 over 2021.

Dosage Form

Introduction

In 2021, Oral segment has the highest revenue of US $16.76 billion and is expected to grow at CAGR of 4.32% by 2027 Topical segment has highest cagr growth of 4.32%.

Oral

Oral segment was valued at US $15.24 billion in 2019 and is projected to grow at 4.32% CAGR over the forecast period to reach US $22.30 billion by 2027. Oral segment represented US $1.52 billion opportunity over 2019-2021 and estimated to create US $5.54 billion opportunity in 2027 over 2021.

Topical

Topical segment was valued at US $13.37 billion in 2019 and is projected to grow at 4.32% CAGR over the forecast period to reach US $19.56 billion by 2027. Topical segment represented US $1.33 billion opportunity over 2019-2021 and estimated to create US $4.86 billion opportunity in 2027 over 2021.